919.3500 35.60 (4.03%)
NSE May 29, 2025 15:59 PM
Volume: 123.5K
 

919.35
4.03%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.
Tatva Chintan Pharma Chem Ltd. has gained 33.94% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended